Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab.
Nathalie Van der MoerenPhilippe SelhorstMy Kieu HaLaura HeiremanPieter-Jan Van GaalDimitri BreemsPieter MeysmanKris LaukensWalter VerstrepenNatasja Van GasseBenson OgunjimiKevin K ArienReinout NaesensPublished in: Viruses (2022)
SARS-CoV-2 persistence in immunocompromised individuals has important clinical implications, but halting immunosuppressive therapy might result in a favourable clinical course. The long-term shedding of viable virus necessitates customized infection prevention measures in these individuals. The observed accelerated accumulation of mutations of the SARS-CoV-2 genome in these patients might facilitate the origin of new VOCs that might subsequently spread in the general community.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- end stage renal disease
- chronic kidney disease
- healthcare
- ejection fraction
- newly diagnosed
- mental health
- prognostic factors
- diffuse large b cell lymphoma
- mesenchymal stem cells
- patient reported outcomes
- bone marrow
- genome wide
- coronavirus disease
- hodgkin lymphoma
- chronic lymphocytic leukemia
- acute respiratory distress syndrome